[ad_1]
Textual content measurement
Eli Lilly
posted third-quarter earnings of $1.94 a share, 2 cents under analysts’ estimates, however the inventory was rising after the drug big boosted its full-year steerage.
Eli Lilly
‘s income within the third quarter was $6.77 billion. Analysts anticipated gross sales of $6.64 billion.
Eli Lilly reported year-earlier earnings of $1.54 a share on income of $5.74 billion.
The corporate stated Tuesday it expects full-year adjusted earnings of $7.95 to $8.05 a share, vs. prior steerage of $7.80 to $8 a share. Income was forecast at $27.2 billion to $27.6 billion.
Eli Lilly stated third-quarter Trulicity income was $1.6 billion, 45% increased than a 12 months earlier and above Wall Avenue estimates.
Income from Covid-19 antibodies was $217.1 million, above forecasts of about $161 million.
The inventory was rising 1.91% to $249.73 in premarket buying and selling.
Write to Joe Woelfel at joseph.woelfel@barrons.com
[ad_2]
Source link